Events and Presentations

iCo trades on the TSX Venture Exchange under the symbol “ICO” and the OTCQB the symbol “ICOTF”

Title	Date
Oral Amphotericin B Candidate	January 1, 2021
Bertilimumab/iCo-008 Project	January 1, 2021
iCo Therapeutics Corporate Presentation	January 1, 2021
Development of a Novel Oral Amphotericin B Formulation (iCo-019) to treat systemic Sciences, Faculty of Medicine, UBC fungal and parasitic infections	December 1, 2020
Phase Ia and Ib Double-Blind Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (ICo-019) in Healthy Human Subjects	October 1, 2020
Assessing the Pharmacokinetics and Biodistribution of Amphotericin B following Oral Administration of three novel oral amphotecrin B formulations to beagle dogs	October 1, 2020